This inventor holds 1 USPTO granted patent. Top assignee: The University of Queensland. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovative Contributions of Jeffrey Mak
Introduction
Jeffrey Mak is a notable inventor based in St Lucia, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of histone deacetylase inhibitors. His work focuses on compounds that have the potential to impact various diseases and disorders associated with Class IIa HDAC activity.
Latest Patents
Jeffrey Mak holds a patent for his invention related to histone deacetylase inhibitors. The patent describes compounds, pharmaceutically acceptable salts, or prodrugs that inhibit the binding or function of Histone Deacetylase (HDAC). These compounds may exhibit selectivity for inhibiting Class IIa versus Class I HDACs. The application also discusses methods of using these compounds, particularly in the prevention of diseases linked to Class IIa HDAC activity. One form of the compounds includes (ortho-phenyl) phenyl hydroxamates, while another is represented in Formula (I), where R1 is a phenyl or cycloalkenyl that may be optionally substituted. Jeffrey Mak's innovative approach in this area has the potential to lead to new therapeutic options.
Career Highlights
Throughout his career, Jeffrey Mak has demonstrated a commitment to advancing scientific knowledge and innovation. His work at The University of Queensland has positioned him as a key figure in research related to histone deacetylase inhibitors. His contributions have not only added to the academic community but also hold promise for practical applications in medicine.
Collaborations
Jeffrey Mak has collaborated with esteemed colleagues, including Ligong Liu and Robert C Reid. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in their respective fields.
Conclusion
In summary, Jeffrey Mak is an accomplished inventor whose work on histone deacetylase inhibitors represents a significant advancement in pharmaceutical research. His contributions have the potential to impact the treatment of various diseases, showcasing the importance of innovation in the medical field.